TY - JOUR AU - Welin, M. AU - Kosinska, U. AU - Mikkelsen, N. E. AU - Carnrot, C. AU - Zhu, C. AU - Wang, L. AU - Eriksson, S. AU - Munch-Petersen, B. AU - Eklund, H. PY - 2004 DA - 2004// TI - Structures of thymidine kinase 1 of human and mycoplasmic origin JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0406332102 DO - 10.1073/pnas.0406332102 ID - Welin2004 ER - TY - JOUR AU - Bello, L. J. PY - 1974 DA - 1974// TI - Regulation of thymidine kinase synthesis in human cells JO - Exp Cell Res VL - 89 UR - https://doi.org/10.1016/0014-4827(74)90790-3 DO - 10.1016/0014-4827(74)90790-3 ID - Bello1974 ER - TY - JOUR AU - Munch-Petersen, B. AU - Tyrsted, G. PY - 1977 DA - 1977// TI - Induction of thymidine kinases in phytohaemagglutinin-stimulated human lymphocytes JO - Biochim Biophys Acta VL - 478 UR - https://doi.org/10.1016/0005-2787(77)90152-6 DO - 10.1016/0005-2787(77)90152-6 ID - Munch-Petersen1977 ER - TY - JOUR AU - Sherley, J. L. AU - Kelly, T. J. PY - 1988 DA - 1988// TI - Regulation of human thymidine kinase during the cell cycle JO - J Biol Chem VL - 263 ID - Sherley1988 ER - TY - JOUR AU - Ke, P. Y. AU - Chang, Z. F. PY - 2004 DA - 2004// TI - Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway JO - Mol Cell Biol VL - 24 UR - https://doi.org/10.1128/MCB.24.2.514-526.2004 DO - 10.1128/MCB.24.2.514-526.2004 ID - Ke2004 ER - TY - JOUR AU - Nisman, B. AU - Allweis, T. AU - Kadouri, L. AU - Mali, B. AU - Hamburger, T. AU - Baras, M. AU - Gronowitz, S. AU - Peretz, T. PY - 2013 DA - 2013// TI - Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients JO - Clin Chem Lab Med VL - 51 UR - https://doi.org/10.1515/cclm-2012-0162 DO - 10.1515/cclm-2012-0162 ID - Nisman2013 ER - TY - JOUR AU - Nisman, B. AU - Allweis, T. AU - Kaduri, L. AU - Maly, B. AU - Gronowitz, S. AU - Hamburger, T. AU - Peretz, T. PY - 2010 DA - 2010// TI - Serum thymidine kinase 1 activity in breast cancer JO - Cancer Biomark VL - 7 UR - https://doi.org/10.3233/CBM-2010-0148 DO - 10.3233/CBM-2010-0148 ID - Nisman2010 ER - TY - JOUR AU - Nisman, B. AU - Appelbaum, L. AU - Yutkin, V. AU - Nechushtan, H. AU - Hubert, A. AU - Uziely, B. AU - Pode, D. AU - Peretz, T. PY - 2016 DA - 2016// TI - Serum thymidine kinase 1 activity following nephrectomy for renal cell carcinoma and radiofrequency ablation of metastases to lung and liver JO - Anticancer Res VL - 36 ID - Nisman2016 ER - TY - JOUR AU - Nisman, B. AU - Nechushtan, H. AU - Biran, H. AU - Gantz-Sorotsky, H. AU - Peled, N. AU - Gronowitz, S. AU - Peretz, T. PY - 2014 DA - 2014// TI - Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000276 DO - 10.1097/JTO.0000000000000276 ID - Nisman2014 ER - TY - JOUR AU - Stelmach, P. AU - Błoński, J. Z. AU - Wawrzyniak, E. AU - Schweiger, P. E. AU - Wilandt, A. AU - Majak, P. E. AU - Robak, T. PY - 2016 DA - 2016// TI - Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia JO - Postepy Hig Med Dosw (Online) VL - 70 ID - Stelmach2016 ER - TY - JOUR AU - DeMichele, A. AU - Clark, A. S. AU - Tan, K. S. AU - Heitjan, D. F. AU - Gramlich, K. AU - Gallagher, M. AU - Lal, P. AU - Feldman, M. AU - Zhang, P. AU - Colameco, C. PY - 2015 DA - 2015// TI - CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2258 DO - 10.1158/1078-0432.CCR-14-2258 ID - DeMichele2015 ER - TY - JOUR AU - Hortobagyi, G. N. AU - Stemmer, S. M. AU - Burris, H. A. AU - Yap, Y. S. AU - Sonke, G. S. AU - Paluch-Shimon, S. AU - Campone, M. AU - Blackwell, K. L. AU - André, F. AU - Winer, E. P. PY - 2016 DA - 2016// TI - Ribociclib as first-line therapy for HR-positive, advanced breast cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1609709 DO - 10.1056/NEJMoa1609709 ID - Hortobagyi2016 ER - TY - JOUR AU - Cristofanilli, M. AU - Turner, N. C. AU - Bondarenko, I. AU - Ro, J. AU - Im, S. A. AU - Masuda, N. AU - Colleoni, M. AU - DeMichele, A. AU - Loi, S. AU - Verma, S. PY - 2016 DA - 2016// TI - Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00613-0 DO - 10.1016/S1470-2045(15)00613-0 ID - Cristofanilli2016 ER - TY - JOUR AU - Finn, R. S. AU - Martin, M. AU - Rugo, H. S. AU - Jones, S. AU - Im, S. A. AU - Gelmon, K. AU - Harbeck, N. AU - Lipatov, O. N. AU - Walshe, J. M. AU - Moulder, S. PY - 2016 DA - 2016// TI - Palbociclib and letrozole in advanced breast cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1607303 DO - 10.1056/NEJMoa1607303 ID - Finn2016 ER - TY - JOUR AU - Patnaik, A. AU - Rosen, L. S. AU - Tolaney, S. M. AU - Tolcher, A. W. AU - Goldman, J. W. AU - Gandhi, L. AU - Papadopoulos, K. P. AU - Beeram, M. AU - Rasco, D. W. AU - Hilton, J. F. PY - 2016 DA - 2016// TI - Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0095 DO - 10.1158/2159-8290.CD-16-0095 ID - Patnaik2016 ER - TY - JOUR AU - Sledge, G. W. AU - Toi, M. AU - Neven, P. AU - Sohn, J. AU - Inoue, K. AU - Pivot, X. AU - Burdaeva, O. AU - Okera, M. AU - Masuda, N. AU - Kaufman, P. A. PY - 2017 DA - 2017// TI - MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.7585 DO - 10.1200/JCO.2017.73.7585 ID - Sledge2017 ER - TY - JOUR AU - Finn, R. S. AU - Aleshin, A. AU - Slamon, D. J. PY - 2016 DA - 2016// TI - Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-015-0661-5 DO - 10.1186/s13058-015-0661-5 ID - Finn2016 ER - TY - JOUR AU - O’Leary, B. AU - Finn, R. S. AU - Turner, N. C. PY - 2016 DA - 2016// TI - Treating cancer with selective CDK4/6 inhibitors JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.26 DO - 10.1038/nrclinonc.2016.26 ID - O’Leary2016 ER - TY - JOUR AU - Ma, C. X. AU - Gao, F. AU - Luo, J. AU - Northfelt, D. W. AU - Goetz, M. P. AU - Forero, A. AU - Hoog, J. AU - Naughton, M. AU - Ademuyiwa, F. AU - Suresh, R. PY - 2017 DA - 2017// TI - NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3206 DO - 10.1158/1078-0432.CCR-16-3206 ID - Ma2017 ER - TY - JOUR AU - Ellis, M. J. AU - Suman, V. J. AU - Hoog, J. AU - Goncalves, R. AU - Sanati, S. AU - Creighton, C. J. AU - DeSchryver, K. AU - Crouch, E. AU - Brink, A. AU - Watson, M. PY - 2017 DA - 2017// TI - Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.69.4406 DO - 10.1200/JCO.2016.69.4406 ID - Ellis2017 ER - TY - JOUR AU - Bjohle, J. AU - Bergqvist, J. AU - Gronowitz, J. S. AU - Johansson, H. AU - Carlsson, L. AU - Einbeigi, Z. AU - Linderholm, B. AU - Loman, N. AU - Malmberg, M. AU - Soderberg, M. PY - 2013 DA - 2013// TI - Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial JO - Breast Cancer Res Treat VL - 139 UR - https://doi.org/10.1007/s10549-013-2579-x DO - 10.1007/s10549-013-2579-x ID - Bjohle2013 ER - TY - JOUR AU - Bland, J. M. AU - Altman, D. G. PY - 1995 DA - 1995// TI - Statistics notes: Calculating correlation coefficients with repeated observations: Part 1—correlation within subjects JO - BMJ VL - 310 UR - https://doi.org/10.1136/bmj.310.6977.446 DO - 10.1136/bmj.310.6977.446 ID - Bland1995 ER - TY - JOUR AU - Luo, J. AU - D’Angelo, G. AU - Gao, F. AU - Ding, J. AU - Xiong, C. PY - 2015 DA - 2015// TI - Bivariate correlation coefficients in family-type clustered studies JO - Biom J VL - 57 UR - https://doi.org/10.1002/bimj.201400131 DO - 10.1002/bimj.201400131 ID - Luo2015 ER - TY - JOUR AU - Berghuis, A. M. AU - Koffijberg, H. AU - Prakash, J. AU - Terstappen, L. W. AU - IJzerman, M. J. PY - 2017 DA - 2017// TI - Detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility JO - Int J Mol Sci VL - 18 UR - https://doi.org/10.3390/ijms18020363 DO - 10.3390/ijms18020363 ID - Berghuis2017 ER - TY - JOUR AU - Cappelletti, V. AU - Appierto, V. AU - Tiberio, P. AU - Fina, E. AU - Callari, M. AU - Daidone, M. G. PY - 2015 DA - 2015// TI - Circulating biomarkers for prediction of treatment response JO - J Natl Cancer Inst Monogr VL - 2015 UR - https://doi.org/10.1093/jncimonographs/lgv006 DO - 10.1093/jncimonographs/lgv006 ID - Cappelletti2015 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Aufderklamm, S. AU - Todenhofer, T. AU - Gakis, G. AU - Kruck, S. AU - Hennenlotter, J. AU - Stenzl, A. AU - Schwentner, C. PY - 2012 DA - 2012// TI - Thymidine kinase and cancer monitoring JO - Cancer Lett VL - 316 UR - https://doi.org/10.1016/j.canlet.2011.10.025 DO - 10.1016/j.canlet.2011.10.025 ID - Aufderklamm2012 ER - TY - JOUR AU - Mao, Y. AU - Wu, J. AU - Wang, N. AU - He, L. AU - Wu, C. AU - He, Q. AU - Skog, S. PY - 2002 DA - 2002// TI - A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer JO - Cancer Invest VL - 20 UR - https://doi.org/10.1081/CNV-120005905 DO - 10.1081/CNV-120005905 ID - Mao2002 ER - TY - JOUR AU - He, Q. AU - Zou, L. AU - Zhang, P. A. AU - Lui, J. X. AU - Skog, S. AU - Fornander, T. PY - 2000 DA - 2000// TI - The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody JO - Int J Biol Markers VL - 15 ID - He2000 ER - TY - JOUR AU - He, Q. AU - Fornander, T. AU - Johansson, H. AU - Johansson, U. AU - Hu, G. Z. AU - Rutqvist, L. E. AU - Skog, S. PY - 2006 DA - 2006// TI - Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer JO - Anticancer Res VL - 26 ID - He2006 ER - TY - JOUR AU - Korkmaz, T. AU - Seber, S. AU - Okutur, K. AU - Basaran, G. AU - Yumuk, F. AU - Dane, F. AU - Ones, T. AU - Polat, O. AU - Madenci, O. C. AU - Demir, G. PY - 2013 DA - 2013// TI - Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer JO - Biomarkers VL - 18 UR - https://doi.org/10.3109/1354750X.2012.738250 DO - 10.3109/1354750X.2012.738250 ID - Korkmaz2013 ER - TY - JOUR AU - Lim, J. S. AU - Turner, N. C. AU - Yap, T. A. PY - 2016 DA - 2016// TI - CDK4/6 inhibitors: promising opportunities beyond breast cancer JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0563 DO - 10.1158/2159-8290.CD-16-0563 ID - Lim2016 ER - TY - JOUR AU - Turner, N. C. AU - Ro, J. AU - André, F. AU - Loi, S. AU - Verma, S. AU - Iwata, H. AU - Harbeck, N. AU - Loibl, S. AU - Huang Bartlett, C. AU - Zhang, K. PY - 2015 DA - 2015// TI - Palbociclib in hormone-receptor-positive advanced breast cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1505270 DO - 10.1056/NEJMoa1505270 ID - Turner2015 ER - TY - JOUR AU - Prall, O. W. AU - Sarcevic, B. AU - Musgrove, E. A. AU - Watts, C. K. AU - Sutherland, R. L. PY - 1997 DA - 1997// TI - Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2 JO - J Biol Chem VL - 272 UR - https://doi.org/10.1074/jbc.272.16.10882 DO - 10.1074/jbc.272.16.10882 ID - Prall1997 ER - TY - JOUR AU - Watts, C. K. AU - Sweeney, K. J. AU - Warlters, A. AU - Musgrove, E. A. AU - Sutherland, R. L. PY - 1994 DA - 1994// TI - Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells JO - Breast Cancer Res Treat VL - 31 UR - https://doi.org/10.1007/BF00689680 DO - 10.1007/BF00689680 ID - Watts1994 ER -